MY184908A - Use of a probiotic metabolite for slowing signs of aging - Google Patents

Use of a probiotic metabolite for slowing signs of aging

Info

Publication number
MY184908A
MY184908A MYPI2018703091A MYPI2018703091A MY184908A MY 184908 A MY184908 A MY 184908A MY PI2018703091 A MYPI2018703091 A MY PI2018703091A MY PI2018703091 A MYPI2018703091 A MY PI2018703091A MY 184908 A MY184908 A MY 184908A
Authority
MY
Malaysia
Prior art keywords
aging
slowing
signs
metabolite
probiotic
Prior art date
Application number
MYPI2018703091A
Inventor
Yong Ha Park
Original Assignee
Aqurate Ingredients Intl M Sdn Bhd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aqurate Ingredients Intl M Sdn Bhd filed Critical Aqurate Ingredients Intl M Sdn Bhd
Priority to MYPI2018703091A priority Critical patent/MY184908A/en
Priority to CN201910590707.5A priority patent/CN110870859B/en
Priority to PCT/KR2019/011130 priority patent/WO2020050553A1/en
Priority to CN201980056940.3A priority patent/CN112930392B/en
Priority to KR1020217006268A priority patent/KR20210042334A/en
Publication of MY184908A publication Critical patent/MY184908A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/065—Microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
    • C12P7/42—Hydroxy-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
    • C12P7/56—Lactic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/25—Lactobacillus plantarum
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)

Abstract

The present invention relates to a Lactobacillus plantarum strain DR7 metabolite comprising 2-hydroxyisocapric acid and 3-phenyllactic acid and its use for providing slowing down of aging.
MYPI2018703091A 2018-09-03 2018-09-03 Use of a probiotic metabolite for slowing signs of aging MY184908A (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
MYPI2018703091A MY184908A (en) 2018-09-03 2018-09-03 Use of a probiotic metabolite for slowing signs of aging
CN201910590707.5A CN110870859B (en) 2018-09-03 2019-07-02 Probiotic metabolites for delaying signs of aging
PCT/KR2019/011130 WO2020050553A1 (en) 2018-09-03 2019-08-30 Probiotic strain for upper respiratory tract infection, stress, anxiety, memory and cognitive dysfunctions, and ageing
CN201980056940.3A CN112930392B (en) 2018-09-03 2019-08-30 Probiotics for upper respiratory tract infections, stress, anxiety, memory and cognitive dysfunction and aging
KR1020217006268A KR20210042334A (en) 2018-09-03 2019-08-30 Probiotic strain for upper respiratory tract infection, stress, anxiety, memory and cognitive dysfunction, and aging

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MYPI2018703091A MY184908A (en) 2018-09-03 2018-09-03 Use of a probiotic metabolite for slowing signs of aging

Publications (1)

Publication Number Publication Date
MY184908A true MY184908A (en) 2021-04-30

Family

ID=69716369

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2018703091A MY184908A (en) 2018-09-03 2018-09-03 Use of a probiotic metabolite for slowing signs of aging

Country Status (4)

Country Link
KR (1) KR20210042334A (en)
CN (2) CN110870859B (en)
MY (1) MY184908A (en)
WO (1) WO2020050553A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6994116B2 (en) * 2018-02-02 2022-02-04 コバイオラブス，インコーポレーテッド Lactobacillus plantarum KBL396 strain and its uses
US20240012008A1 (en) * 2020-10-30 2024-01-11 The Regents Of The University Of California Compositions and methods for diagnosing and treating patients with a history of early life adversity
TW202241477A (en) * 2020-12-16 2022-11-01 日商明治股份有限公司 Composition for improving inflammation of brain tissue
CN112915109B (en) * 2021-01-21 2023-03-24 吉林省农业科学院 Application of lactobacillus plantarum DP189 in preparation of medicine for preventing and/or treating Alzheimer disease
CN113337427A (en) * 2021-06-03 2021-09-03 海南大学 Lactobacillus plantarum HNU082, composition and application thereof
CN113337428B (en) * 2021-06-03 2023-06-06 海南大学 Lactobacillus plantarum HNU082 and application thereof
US20230414685A1 (en) * 2022-05-26 2023-12-28 Pouda Biotech Llc Lactobacillus plantarum pda6 having neurological effects and compositions including the same
CN115181695B (en) * 2022-06-27 2023-08-29 广东粤港澳大湾区国家纳米科技创新研究院 Lactobacillus plantarum5b4m2 and application thereof
CN115838653A (en) * 2022-07-11 2023-03-24 四川维创天益生物科技有限公司 Lactobacillus plantarum GM11 for improving bad mood and application thereof
CN115089619A (en) * 2022-07-18 2022-09-23 南昌大学 Application of lactobacillus plantarum ZDY2013 in preparation with function of relieving non-alcoholic fatty liver disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040001817A1 (en) * 2002-05-14 2004-01-01 Giampapa Vincent C. Anti-aging nutritional supplement
KR100654427B1 (en) * 2005-09-23 2006-12-06 심명식 Lactobacillus plantarum cu03 kacc 91103 having provention of formating a foul odor and a deodorizing acitivy
WO2009068474A1 (en) * 2007-11-29 2009-06-04 Carinsa. Creaciones Aromáticas Industriales, S. A. Strains of lactobacillus plantarum as probiotics with immunomodulatory specific effect
KR101500974B1 (en) * 2014-08-22 2015-03-13 (주) 에이투젠 Lactobacillus plantarum HAC01 having anti-inflammation and metabolic disease improvement effect and uses thereof
CN105505814B (en) * 2015-11-30 2020-01-17 南昌大学 Lactobacillus plantarum for delaying senescence
CN106265763A (en) * 2016-08-31 2017-01-04 泰安大凡神农制药有限公司 There is slow down aging and the compositions of skin-care functional and application thereof

Also Published As

Publication number Publication date
CN112930392A (en) 2021-06-08
WO2020050553A1 (en) 2020-03-12
CN110870859A (en) 2020-03-10
CN112930392B (en) 2023-04-28
KR20210042334A (en) 2021-04-19
CN110870859B (en) 2023-04-18

Similar Documents

Publication Publication Date Title
MY184908A (en) Use of a probiotic metabolite for slowing signs of aging
SG11202010944RA (en) Lactobacillus paracasei strain and use thereof
EP3747988A4 (en) Lactobacillus plantarum kbl396 strain and use thereof
MX2018014476A (en) Bacillus subtilis strain with probiotic activity.
EP3798298A4 (en) Lactobacillus gasseri kbl697 strain and use thereof
RS54478B1 (en) Isolated microorganism strain lactobacillus plantarum mcc1 dsm 23881 and its use
NZ712959A (en) Probiotic strains for use in treatment or prevention of osteoporosis
PH12016501777A1 (en) Novel lactobacillus paracasei strain
EA201290623A1 (en) Lactobacilli with antioxidant action
ZA201601119B (en) Strain of lactobacillus pentosus as probiotic
ZA202105310B (en) Probiotic compositions comprising lactobacillus reuteri strains and methods of use
MX2018014497A (en) Bacillus licheniformis strain with probiotic activity.
MX2016014991A (en) Compositions containing boric acid and a mixture of lactobacillus.
MX2015014266A (en) Composition comprising a combination of an elder extract and a strain of lactobacillus rhamnosus.
SG11202000123SA (en) Lactobacillus plantarum cjlp475 strain having antiviral and immunomodulatory effects and composition comprising the same
CO2017007338A2 (en) Composition comprising two strains of the microbial species lactobacillus rhamnosus and bifidobacterium longum capable of increasing male fertility
EP3601525C0 (en) Probiotic lactobacillus casei strain and its uses
EP3027734B8 (en) Isolated microorganism strain lactobacillus plantarum tak 59 ncimb42150 and its use
AU2019263623A8 (en) Probiotic Bifidobacterium breve strain and compositions comprising said strain
EP3620512A4 (en) Composition comprising lactobacillus plantarum cjlp475 strain and lactobacillus plantarum cjlp17 strain and use thereof
IL260181A (en) Compositions and methods of use of novel strains of lactobacillus fermentum
RS62716B1 (en) Variant of oleaginous yeast and its use for the production of lipids
DK3168292T3 (en) NEW LACTOBACILLUS PLANTARUM STRAIN AMT14 AND COMPOSITION CONTAINING THE STOCK OF LACTOBACILLUS PLANTARUM AMT14
PH12014502244A1 (en) Novel separated bacillus linheniformis and probiotics using same
MX2018012312A (en) Lactobacillus rhamnosus for use in preparation of fermented products.